Evidence map›Paper›PMID 27099955›Full record

Trial reportJAMA ophthalmology2016

Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Maureen G Maguire, Gui-Shuang Ying, Glenn J Jaffe, Cynthia A Toth, Ebenezer Daniel, Juan Grunwald, Daniel F Martin, Stephanie A Hagstrom, CATT Research Group

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00593450 (Comparison of Age-related Macular Degeneration Treatments Trials), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00593450 phase3completednot on this map

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)

TypeinterventionalSponsorUniversity of PennsylvaniaRan2008 to 2015Enrolled1,208ConditionsAge Related Macular DegenerationArmsranibizumab, bevacizumab
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Genetic context modulates aging and degeneration in the murine retina.bioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Maureen G MaguireDepartment of Ophthalmology, University of Pennsylvania, Philadelphia.
Gui-Shuang YingDepartment of Ophthalmology, University of Pennsylvania, Philadelphia.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina.
Cynthia A TothDepartment of Ophthalmology, Duke University, Durham, North Carolina.
Ebenezer DanielDepartment of Ophthalmology, University of Pennsylvania, Philadelphia.
Juan GrunwaldDepartment of Ophthalmology, University of Pennsylvania, Philadelphia.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Stephanie A HagstromCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
CATT Research Group
University of Pennsylvania · USDuke University · USCleveland Clinic · USCleveland Eye Clinic · US

Funding

Coordinating Center for the Comparison of AMD Treatments TrialsU10EY017823 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2006 to 2012
$19.2M
Photograph Reading Center for the Comparison of AMD Treatment TrialsU10EY017826 · NEI · UNIVERSITY OF PENNSYLVANIA · PI GRUNWALD, JUAN E · 2006 to 2013
$2.8M
Comparison of AMD Treatment Trials-OCT Reading CenterU10EY017825 · NEI · DUKE UNIVERSITY · PI JAFFE, GLENN · 2006 to 2013
$2.3M
Chair Grant for the Comparison of AMD Treatment TrialsU10EY017828 · NEI · EMORY UNIVERSITY · PI MARTIN, DANIEL F · 2006 to 2012
$1.9M
Secondary Data Analysis of the Data from Comparison of AMD Treatments TrialsR21EY023689 · NEI · UNIVERSITY OF PENNSYLVANIA · PI YING, GUI-SHUANG · 2013 to 2014
$436k
NEI NIH HHS R21 EY023689NEI NIH HHS U10 EY017823NEI NIH HHS U10 EY017825NEI NIH HHS U10 EY017826
6 · The paper itself

Abstract

importanceSingle-nucleotide polymorphisms (SNPs) associated with the CFH, ARMS2, C3, LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the association of these SNPs with angiographic features of neovascular AMD has been inconsistent in previous studies, and to date, no studies have addressed their association with features on optical coherence tomography.

objectiveTo evaluate the influence of genotype of SNPs previously associated with AMD on the phenotype of neovascular lesions. DESIGN, SETTING, AND

participantsParticipants for this cross-sectional study were recruited from the 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomized clinical trial. Eligibility criteria for CATT specified that eyes have choroidal neovascularization and visual acuity between 20/25 and 20/320. A subgroup of 835 patients provided blood samples from July 2010 through September 2011 and were genotyped for the SNPs rs1061170 (CFH), rs10490924 (ARMS2),rs2230199 (C3), rs10468017 (LIPC), rs4151667 (CFB), rs547154 (C2) using TaqMan SNP genotyping assays. Data analysis was initiated in November 2013 and completed in January 2016. MAIN OUTCOMES AND MEASURES: Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascularization and total lesion, retinal angiomatous proliferation) and on time-domain optical coherence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age.

resultsA total of 835 (73%) of 1150 CATT patients were genotyped. Mean age decreased with the number of risk alleles for CFH (P < .001), ARMS2 (P < .001), and C3 (P = .005). The following results were found as the number of risk alleles increased from 0 to 1 to 2. For CFH, mean total thickness decreased from 476 to 476 to 434 µm (P = .01; adjusted for age, sex, and smoking status). For ARMS2, the mean area of the total lesion increased from 2.0 to 2.8 to 2.4 mm2 (P = .03), the proportion with retinal angiomatous proliferation lesions increased from 8% to 10% to 12% (P = .05), and the proportion with intraretinal fluid increased from 72% to 71% to 82% (P = .008). For C3, the proportion with intraretinal fluid decreased from 78% to 69% to 64% (P = .001), and the mean retinal thickness decreased from 225 to 207 to 197 µm (P = .02). CONCLUSIONS AND RELEVANCE: CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in CATT. Previously identified associations of ARMS2 and CFH with type of choroidal neovascularization on fluorescein angiography were not confirmed. New associations with OCT features identified in CATT need confirmation to establish whether a true association exists.

trial registrationclinicaltrials.gov Identifier: NCT00593450.

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overComplement C2Complement C3Complement Factor BComplement Factor HCross-Sectional StudiesFemaleFluorescein AngiographyGenotypeGenotyping TechniquesHumansLipaseMalePhenotypeARMS2 protein, humanCFH protein, humanComplement C2Complement C3Complement Factor BComplement Factor HLipaseLIPC protein, humanProteins

Identifiers

PMID27099955
PMCPMC6005698
OpenAlexW2340191798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.